Exploring the role of nerve growth factor in multiple sclerosis: Implications in myelin repair

CNS and Neurological Disorders - Drug Targets

Volumn 12, Issue 8, 2013, Pages 1242-1256

  Acosta, C M R ^a   Cortes, C ^a   MacPhee, H ^a   Namaka, M P ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Cytokines; Multiple sclerosis; Myelin; Nerve growth factor; Neurotrophins; Oligodendrocytes; Re myelination

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; CYTOKINE; FINGOLIMOD; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB; NERVE GROWTH FACTOR; NEUROTROPHIN; NEUROTROPHIN RECEPTOR P75; PROTEOLIPID PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; AUTOIMMUNITY; BLOOD BRAIN BARRIER; CD4+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM; DRUG TARGETING; HUMAN; IMMUNOMODULATION; MOLECULAR INTERACTION; MULTIPLE SCLEROSIS; MYELIN SHEATH; MYELINATION; NERVE FIBER; NERVE FIBER REGENERATION; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; OLIGODENDROCYTE PRECURSOR CELL; OLIGODENDROGLIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; REMYELINIZATION; SCHWANN CELL; ANIMAL; DRUG EFFECTS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; AUTOIMMUNITY; HUMANS; MULTIPLE SCLEROSIS; MYELIN SHEATH; NERVE GROWTH FACTOR;

EID: 84891720484     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273113129990087     Document Type: Article

References (250)

1. Zhu, W.; Le Dorze, J.A.; Prout, M.; Frost, E.E.; Namaka, M.P. An Overview of Relapsing Remitting Multiple Sclerosis (RRMS) and current treatment options. Pharm. Pract., 2010, 9, CE1-CE7.
2. Namaka, M.; Turcotte, D.; Leong, C.; Grossberndt, A.; Klassen, D. Multiple sclerosis: etiology and treatment strategies. Consult. Pharm., 2008, 23 (11), 886-896.
3. Namaka, M.P.; Ethans, K.; Jensen, B.; Esfahani, F.; Frost, E.E. In: Multiple Sclerosis, Canadian Pharmacists Association Publishers, Inc, Ottawa, 2011; pp. 309-319.
4. Lafaille, J.J.; Keere, F.V.; Hsu, A.L.; Baron, J.L.; Haas, W.; Raine, C.S.; Tonegawa, S. Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J. Exp. Med., 1997, 186 (2), 307-312.
5. Kebir, H.; Kreymborg, K.; Ifergan, I.; Dodelet-Devillers, A.; Cayrol, R.; Bernard, M.; Giuliani, F.; Arbour, N.; Becher, B.; Prat, A. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med., 2007, 13 (10), 1173-1175.
6. Lock, C.; Hermans, G.; Pedotti, R.; Brendolan, A.; Schadt, E.; Garren, H.; Langer-Gould, A.; Strober, S.; Cannella, B.; Allard, J.; Klonowski, P.; Austin, A.; Lad, N.; Kaminski, N.; Galli, S.J.; Oksenberg, J.R.; Raine, C.S.; Heller, R.; Steinman, L. Genemicroarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med., 2002, 8 (5), 500-508.
7. Ishizu, T.; Osoegawa, M.; Mei, F.J.; Kikuchi, H.; Tanaka, M.; Takakura, Y.; Minohara, M.; Murai, H.; Mihara, F.; Taniwaki, T.; Kira, J. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain, 2005, 128 (Pt 5), 988-1002.
8. Matusevicius, D.; Kivisakk, P.; He, B.; Kostulas, N.; Ozenci, V.; Fredrikson, S.; Link, H. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult. Scler., 1999, 5 (2), 101-104.
9. Traugott, U.; Reinherz, E.L.; Raine, C.S. Multiple sclerosis: distribution of T cell subsets within active chronic lesions. Science, 1983, 219 (4582), 308-310.
10. + T cells in cerebrospinal fluid from multiple sclerosis patients. Brain, 2002, 125 (Pt 3), 538-550.
11. + T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med., 2000, 192 (3), 393-404.
12. + T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc. Natl. Acad. Sci. USA, 2004, 101 (8), 2428-2433.
13. Booss, J.; Esiri, M.M.; Tourtellotte, W.W. Mason, D.Y. Immunohistological analysis of T lymphocyte subsets in the central nervous system in chronic progressive multiple sclerosis. J. Neurol. Sci., 1983, 62 (1-3), 219-232.
14. Loma, I.; Heyman, R. Multiple sclerosis: pathogenesis and treatment. Curr. Neuropharmacol., 2011, 9 (3), 409-416.
15. Genain, C.P.; Cannella, B.; Hauser, S.L.; Raine, C.S. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med., 1999, 5 (2), 170-175.
16. Steinman, L. Assessment of animal models for MS and demyelinating disease in the design of rational therapy. Neuron, 1999, 24 (3), 511-514.
17. Stromnes, I.M.; Goverman, J.M. Active induction of experimental allergic encephalomyelitis. Nat. Protoc., 2006, 1 (4), 1810-1819.
18. Gold, R.; Linington, C.; Lassmann, H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain, 2006, 129 (Pt 8), 1953-1971.
19. Waksman, B.H.; Adams, R.D. A histologic study of the early lesion in experimental allergic encephalomyelitis in the guinea pig and rabbit. Am. J. Pathol., 1962, 41, 135-162.
20. Franklin, R.J.; Ffrench-Constant, C.; Edgar, J.M.; Smith, K.J. Neuroprotection and repair in multiple sclerosis. Nat. Rev. Neurol., 2012, 8 (11), 624-634.
21. van Noort, J.M.; Baker, D.; Amor, S. Mechanisms in the development of multiple sclerosis lesions: reconciling autoimmune and neurodegenerative factors. CNS Neurol. Disord. Drug Targets, 2012, 11 (5), 556-569.
22. Kroner, A.; Schwab, N.; Ip, C.W.; Ortler, S.; Gobel, K.; Nave, K.A.; Maurer, M.; Martini, R.; Wiendl, H. Accelerated course of experimental autoimmune encephalomyelitis in PD-1-deficient central nervous system myelin mutants. Am. J. Pathol., 2009, 174 (6), 2290-2299.
23. Franklin, R.J. Why does remyelination fail in multiple sclerosis? Nat. Rev. Neurosci., 2002, 3 (9), 705-714.
24. Lu, J.; Kurejova, M.; Wirotanseng, L.N.; Linker, R.A.; Kuner, R.; Tappe-Theodor, A. Pain in experimental autoimmune encephalitis: a comparative study between different mouse models. J. Neuroinflammation, 2012, 9 (1), 233.
25. Stepanov, A.V.; Belogurov, A.A.; Mamedov, A.E.; Melamed, D.; Smirnov, I.V.; Kuzina, E.S.; Genkin, D.D.; Boiko, A.N.; Sharanova, S.N.; Bacon, A.; Ponomarenko, N.A.; Gabibov, A.G. Therapeutic effect of encapsulated into the nanocontainers MBP immunodominant peptides on EAE development in DA rats. Bioorg. Khim., 2012, 38 (3), 306-314.
26. Ransohoff, R.M. Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology. Immunity, 2009, 31 (5), 711-721.
27. Genain, C.P.; Hauser, S.L. Allergic Encephalomyelitis in Common Marmosets: Pathogenesis of a Multiple Sclerosis-like Lesion. Methods, 1996, 10 (3), 420-434.
28. Ben-Hur, T.; van Heeswijk, R.B.; Einstein, O.; Aharonowiz, M.; Xue, R.; Frost, E.E.; Mori, S.; Reubinoff, B.E.; Bulte, J.W. Serial in vivo MR tracking of magnetically labeled neural spheres transplanted in chronic EAE mice. Magn. Reson. Med., 2007, 57 (1), 164-171.
29. Costa, O.; Divoux, D.; Ischenko, A.; Tron, F.; Fontaine, M. Optimization of an animal model of experimental autoimmune encephalomyelitis achieved with a multiple MOG (35-55) peptide in C57BL6/J strain of mice. J. Autoimmun., 2003, 20 (1), 51-61.
30. Zamvil, S.S.; Steinman, L. The T lymphocyte in experimental allergic encephalomyelitis. Annu. Rev. Immunol., 1990, 8, 579-621.
31. Blankenhorn, E.P.; Butterfield, R.; Case, L.K.; Wall, E.H.; Del Rio, R.; Diehl, S.A.; Krementsov, D.N.; Saligrama, N.; Teuscher, C. Genetics of experimental allergic encephalomyelitis supports the role of T helper cells in multiple sclerosis pathogenesis. Ann. Neurol., 2011, 70 (6), 887-896.
32. Segal, B.M.; Cross, A.H. Fas (t) track to apoptosis in MS: TNF receptors may suppress or potentiate CNS demyelination. Neurology, 2000, 55 (7), 906-907.
33. Merrill, J.E. Proinflammatory and antiinflammatory cytokines in multiple sclerosis and central nervous system acquired immunodeficiency syndrome. J. Immunother., 1992, 12 (3), 167-170.
34. Zeis, T.; Graumann, U.; Reynolds, R.; Schaeren-Wiemers, N. Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection. Brain, 2008, 131 (1), 288-303.
35. Hauser, S.L.; Oksenberg, J.R. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron, 2006, 52 (1), 61-76.
36. Melanson, M.; Miao, P.; Eisenstat, D.; Gong, Y.; Gu, X.; Au, K.; Zhu, W.; Begum, F.; Frost, E.; Namaka, M. Experimental autoimmune encephalomyelitis-induced upregulation of tumor necrosis factor-alpha in the dorsal root ganglia. Mult. Scler., 2009, 15 (10), 1135-1145.
37. Codarri, L.; Fontana, A.; Becher, B. Cytokine networks in multiple sclerosis: lost in translation. Curr. Opin. Neurol., 2010, 23 (3), 205-211.
38. Glabinski, A.R.; Bielecki, B.; Kawczak, J.A.; Tuohy, V.K.; Selmaj, K.; Ransohoff, R.M. Treatment with soluble tumor necrosis factor receptor (sTNFR): Fc/p80 fusion protein ameliorates relapsingremitting experimental autoimmune encephalomyelitis and decreases chemokine expression. Autoimmunity, 2004, 37 (6-7), 465-471.
39. Hickey, W.F. Migration of hematogenous cells through the bloodbrain barrier and the initiation of CNS inflammation. Brain Pathol., 1991, 1 (2), 97-105.
40. Hickey, W.F.; Hsu, B.L.; Kimura, H. T-lymphocyte entry into the central nervous system. J. Neurosci. Res., 1991, 28 (2), 254-260.
41. Goldenberg, P.Z.; Kwon, E.E.; Benjamins, J.A.; Whitaker, J.N.; Quarles, R.H.; Prineas, J.W. Opsonization of normal myelin by anti-myelin antibodies and normal serum. J. Neuroimmunol., 1989, 23 (2), 157-166.
42. Trotter, J.; DeJong, L.J.; Smith, M.E. Opsonization with antimyelin antibody increases the uptake and intracellular metabolism of myelin in inflammatory macrophages. J. Neurochem., 1986, 47 (3), 779-789.
43. Smith, M.E. Phagocytic properties of microglia in vitro: implications for a role in multiple sclerosis and EAE. Microsc. Res. Tech., 2001, 54 (2), 81-94.
44. Ozenci, V.; Kouwenhoven, M.; Link, H. Cytokines in multiple sclerosis: methodological aspects and pathogenic implications. Mult. Scler., 2002, 8 (5), 396-404.
45. Boven, L.A.; Van Meurs, M.; Van Zwam, M.; Wierenga-Wolf, A.; Hintzen, R.Q.; Boot, R.G.; Aerts, J.M.; Amor, S.; Nieuwenhuis, E.E.; Laman, J.D. Myelin-laden macrophages are antiinflammatory, consistent with foam cells in multiple sclerosis. Brain, 2006, 129 (Pt 2), 517-526.
46. McTigue, D.M.; Wei, P.; Stokes, B.T. Proliferation of NG2-positive cells and altered oligodendrocyte numbers in the contused rat spinal cord. J. Neurosci., 2001, 21 (10), 3392-3400.
47. Keirstead, H.S.; Levine, J.M.; Blakemore, W.F. Response of the oligodendrocyte progenitor cell population (defined by NG2 labelling) to demyelination of the adult spinal cord. Glia, 1998, 22 (2), 161-170.
48. Gensert, J.M. Goldman, J.E. Endogenous progenitors remyelinate demyelinated axons in the adult CNS. Neuron, 1997, 19 (1), 197-203.
49. Goldman, J.E.; Zerlin, M.; Newman, S.; Zhang, L.; Gensert, J. Fate determination and migration of progenitors in the postnatal mammalian. CNS. Dev. Neurosci., 1997, 19 (1), 42-48.
50. Horner, P.J.; Power, A.E.; Kempermann, G.; Kuhn, H.G.; Palmer, T.D.; Winkler, J.; Thal, L.J.; Gage, F.H. Proliferation and differentiation of progenitor cells throughout the intact adult rat spinal cord. J. Neurosci., 2000, 20 (6), 2218-2228.
51. Gogate, N.; Verma, L.; Zhou, J.M.; Milward, E.; Rusten, R.; O'Connor, M.; Kufta, C.; Kim, J.; Hudson, L.; Dubois-Dalcq, M. Plasticity in the adult human oligodendrocyte lineage. J. Neurosci., 1994, 14 (8), 4571-4587.
52. Frost, E.E.; Nielsen, J.A.; Le, T.Q.; Armstrong, R.C. PDGF and FGF2 regulate oligodendrocyte progenitor responses to demyelination. J. Neurobiol., 2003, 54 (3), 457-472.
53. Lytle, J.M.; Chittajallu, R.; Wrathall, J.R.; Gallo, V. NG2 cell response in the CNP-EGFP mouse after contusive spinal cord injury. Glia, 2009, 57 (3), 270-285.
54. Ishii, K.; Toda, M.; Nakai, Y.; Asou, H.; Watanabe, M.; Nakamura, M.; Yato, Y.; Fujimura, Y.; Kawakami, Y.; Toyama, Y.; Uyemura, K. Increase of oligodendrocyte progenitor cells after spinal cord injury. J. Neurosci. Res., 2001, 65 (6), 500-507.
55. Messersmith, D.J.; Murtie, J.C.; Le, T.Q.; Frost, E.E.; Armstrong, R.C. Fibroblast growth factor 2 (FGF2) and FGF receptor expression in an experimental demyelinating disease with extensive remyelination. J. Neurosci. Res., 2000, 62 (2), 241-256.
56. Armstrong, R.C.; Le, T.Q.; Frost, E.E.; Borke, R.C.; Vana, A.C. Absence of fibroblast growth factor 2 promotes oligodendroglial repopulation of demyelinated white matter. J. Neurosci., 2002, 22 (19), 8574-8585.
57. Prineas, J.W.; Kwon, E.E.; Goldenberg, P.Z.; Ilyas, A.A.; Quarles, R.H.; Benjamins, J.A.; Sprinkle, T.J. Multiple sclerosis. Oligodendrocyte proliferation and differentiation in fresh lesions. Lab Invest., 1989, 61 (5), 489-503.
58. Johnson, E.S.; Ludwin, S.K. The demonstration of recurrent demyelination and remyelination of axons in the central nervous system. Acta Neuropathol., 1981, 53 (2), 93-98.
59. Raine, C.S.; Moore, G.R.; Hintzen, R.; Traugott, U. Induction of oligodendrocyte proliferation and remyelination after chronic demyelination. Relevance to multiple sclerosis. Lab Invest., 1988, 59 (4), 467-476.
60. Raine, C.S.; Wu, E. Multiple sclerosis: remyelination in acute lesions. J. Neuropathol. Exp. Neurol., 1993, 52 (3), 199-204.
61. Namaka, M.; Leong, C.; Prout, M.; Dorze, J.A.L.; Limerick, M.; Frost, E.; Esfahani, F. Emerging Therapies for the Management of Multiple Sclerosis. Clin. Med. Insights Therap., 2010, 2 (1-13).
62. Merrill, J.E. Proinflammatory and antiinflammatory cytokines in multiple sclerosis and central nervous system acquired immunodeficiency syndrome. J. Immunother., 1992, 12 (3), 167-170.
63. Kuno, R.; Yoshida, Y.; Nitta, A.; Nabeshima, T.; Wang, J.; Sonobe, Y.; Kawanokuchi, J.; Takeuchi, H.; Mizuno, T.; Suzumura, A. The role of TNF-alpha and its receptors in the production of NGF and GDNF by astrocytes. Brain Res., 2006, 1116 (1), 12-18.
64. Woolf, C.J.; Allchorne, A.; Safieh-Garabedian, B.; Poole, S. Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor alpha. Br. J. Pharmacol., 1997, 121 (3), 417-424.
65. Saha, R.; Liu, X.; Pahan, K. Up-regulation of BDNF in Astrocytes by TNF-α: A Case for the Neuroprotective Role of Cytokine. J. Neuroimmune Pharmacol., 2006, 1 (3), 212-222.
66. Aloe, L.; Properzi, F.; Probert, L.; Akassoglou, K.; Kassiotis, G.; Micera, A.; Fiore, M. Learning abilities, NGF and BDNF brain levels in two lines of TNF-alpha transgenic mice, one characterized by neurological disorders, the other phenotypically normal. Brain Res., 1999, 840 (1-2), 125-137.
67. Linker, R.; Gold, R.; Luhder, F. Function of neurotrophic factors beyond the nervous system: inflammation and autoimmune demyelination. Crit. Rev. Immunol., 2009, 29 (1), 43-68.
68. Lykissas, M.G.; Batistatou, A.K.; Charalabopoulos, K.A.; Beris, A.E. The role of neurotrophins in axonal growth, guidance, and regeneration. Curr. Neurovasc. Res., 2007, 4 (2), 143-151.
69. Van't Veer, A.; Du, Y.; Fischer, T.Z.; Boetig, D.R.; Wood, M.R.; Dreyfus, C.F. Brain-derived neurotrophic factor effects on oligodendrocyte progenitors of the basal forebrain are mediated through trkB and the MAP kinase pathway. J. Neurosci. Res., 2009, 87 (1), 69-78.
70. Nakajima, H.; Uchida, K.; Yayama, T.; Kobayashi, S.; Guerrero, A.R.; Furukawa, S.; Baba, H. Targeted retrograde gene delivery of brain-derived neurotrophic factor suppresses apoptosis of neurons and oligodendroglia after spinal cord injury in rats. Spine, 2010, 35 (5), 497-504.
71. Djalali, S.; Holtje, M.; Grosse, G.; Rothe, T.; Stroh, T.; Grosse, J.; Deng, D.R.; Hellweg, R.; Grantyn, R.; Hortnagl, H.; Ahnert-Hilger, G. Effects of brain-derived neurotrophic factor (BDNF) on glial cells and serotonergic neurones during development. J. Neurochem., 2005, 92 (3), 616-627.
72. Cellerino, A.; Carroll, P.; Thoenen, H.; Barde, Y.A. Reduced Size of Retinal Ganglion Cell Axons and Hypomyelination in Mice Lacking Brain-Derived Neurotrophic Factor. Mol. Cell. Neurosci., 1997, 9 (5-6), 397-408.
73. Du, Y.; Lercher, L.D.; Zhou, R.; Dreyfus, C.F. Mitogen-activated protein kinase pathway mediates effects of brain-derived neurotrophic factor on differentiation of basal forebrain oligodendrocytes. J. Neurosci. Res., 2006, 84 (8), 1692-1702.
74. +/- mice exhibit deficits in oligodendrocyte lineage cells of the basal forebrain. Glia, 2010, 58 (7), 848-856.
75. Takei, Y.; Laskey, R. Interpreting crosstalk between TNF-alpha and NGF: potential implications for disease. Trends Mol. Med., 2008, 14 (9), 381-388.
76. Tartaglia, L.A.; Ayres, T.M.; Wong, G.H.; Goeddel, D.V. A novel domain within the 55 kd TNF receptor signals cell death. Cell, 1993, 74 (5), 845-853.
77. Ware, C.F.; VanArsdale, S.; VanArsdale, T.L. Apoptosis mediated by the TNF-related cytokine and receptor families. J. Cell Biochem., 1996, 60 (1), 47-55.
78. Takano, R.; Hisahara, S.; Namikawa, K.; Kiyama, H.; Okano, H.; Miura, M. Nerve growth factor protects oligodendrocytes from tumor necrosis factor-alpha-induced injury through Akt-mediated signaling mechanisms. J. Biol. Chem., 2000, 275 (21), 16360-16365.
79. Matsuoka, Y.; Yokoyama, M.; Kobayashi, H.; Omori, M.; Itano, Y.; Morita, K.; Mori, H.; Nakanishi, T. Expression profiles of BDNF splice variants in cultured DRG neurons stimulated with NGF. Biochem. Biophys. Res. Commun., 2007, 362 (3), 682-688.
80. Kim, H.; Li, Q.; Hempstead, B.L.; Madri, J.A. Paracrine and autocrine functions of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in brain-derived endothelial cells. J. Biol. Chem., 2004, 279 (32), 33538-33546.
81. Tirassa, P.; Triaca, V.; Amendola, T.; Fiore, M.; Aloe, L. EGF and NGF injected into the brain of old mice enhance BDNF and ChAT in proliferating subventricular zone. J. Neurosci. Res., 2003, 72 (5), 557-564.
82. Apfel, S.C.; Wright, D.E.; Wiideman, A.M.; Dormia, C.; Snider, W.D.; Kessler, J.A. Nerve growth factor regulates the expression of brain-derived neurotrophic factor mRNA in the peripheral nervous system. Mol. Cell Neurosci., 1996, 7 (2), 134-142.
83. Michael, G.J.; Averill, S.; Nitkunan, A.; Rattray, M.; Bennett, D.L.; Yan, Q.; Priestley, J.V. Nerve growth factor treatment increases brain-derived neurotrophic factor selectively in TrkA-expressing dorsal root ganglion cells and in their central terminations within the spinal cord. J. Neurosci., 1997, 17 (21), 8476-8490.
84. Paredes, D.; Granholm, A.C.; Bickford, P.C. Effects of NGF and BDNF on baseline glutamate and dopamine release in the hippocampal formation of the adult rat. Brain Res., 2007, 1141, 56-64.
85. Lindsay, R.M. Nerve growth factors (NGF, BDNF) enhance axonal regeneration but are not required for survival of adult sensory neurons. J. Neurosci., 1988, 8 (7), 2394-2405.
86. Takei, Y.; Laskey, R. Tumor necrosis factor alpha regulates responses to nerve growth factor, promoting neural cell survival but suppressing differentiation of neuroblastoma cells. Mol. Biol. Cell, 2008, 19 (3), 855-864.
87. Reichardt, L.F. Neurotrophin-regulated signalling pathways. Philos. Trans. R Soc. Lond. B Biol. Sci., 2006, 361 (1473), 1545-1564.
88. Begum, F.; Zhu, W.; Cortes, C.; Macneil, B.; Namaka, M. Elevation of Tumor Necrosis Factor Alpha in Dorsal Root Ganglia and Spinal Cord is Associated with Neuroimmune Modulation of Pain in an Animal Model of Multiple Sclerosis. J. Neuroimmune Pharmacol., 2013, 8 (3), 677-690.
89. Villoslada, P.; Hauser, S.L.; Bartke, I.; Unger, J.; Heald, N.; Rosenberg, D.; Cheung, S.W.; Mobley, W.C.; Fisher, S.; Genain, C.P. Human Nerve Growth Factor Protects Common Marmosets against Autoimmune Encephalomyelitis by Switching the Balance of T Helper Cell Type 1 and 2 Cytokines within the Central Nervous System. J. Exp. Med., 2000, 191 (10), 1799-1806.
90. Poliak, S.; Peles, E. The local differentiation of myelinated axons at nodes of Ranvier. Nat. Rev. Neurosci., 2003, 4 (12), 968-980.
91. Waxman, S.G. Ritchie, J.M. Molecular dissection of the myelinated axon. Ann. Neurol., 1993, 33 (2), 121-136.
92. Dyer, C.A. The structure and function of myelin: from inert membrane to perfusion pump. Neurochem. Res., 2002, 27 (11), 1279-1292.
93. Jahn, O.; Tenzer, S.; Werner, H.B. Myelin proteomics: molecular anatomy of an insulating sheath. Mol. Neurobiol., 2009, 40 (1), 55-72.
94. Fitzner, D.; Schneider, A.; Kippert, A.; Mobius, W.; Willig, K.I.; Hell, S.W.; Bunt, G.; Gaus, K.; Simons, M. Myelin basic proteindependent plasma membrane reorganization in the formation of myelin. EMBO J., 2006, 25 (21), 5037-5048.
95. Boggs, J.M. Myelin basic protein: a multifunctional protein. Cell Mol. Life Sci., 2006, 63 (17), 1945-1961.
96. Hemmer, B.; Archelos, J.J.; Hartung, H.P. New concepts in the immunopathogenesis of multiple sclerosis. Nat. Rev. Neurosci., 2002, 3 (4), 291-301.
97. Harauz, G.; Ladizhansky, V.; Boggs, J.M. Structural Polymorphism and Multifunctionality of Myelin Basic Protein. Biochemistry, 2009, 48 (34, 8094-8104.
98. Mahon, K.; Burdick, K.E.; Szeszko, P.R. A role for white matter abnormalities in the pathophysiology of bipolar disorder. Neurosci. Biobehav. Rev., 2010, 34 (4), 533-554.
99. Min, Y.; Kristiansen, K.; Boggs, J.M.; Husted, C.; Zasadzinski, J.A.; Israelachvili, J. Interaction forces and adhesion of supported myelin lipid bilayers modulated by myelin basic protein. Proc. Natl. Acad. Sci. USA, 2009, 106 (9), 3154-3159.
100. Keita, M.; Magy, L.; Heape, A.; Richard, L.; Piaser, M.; Vallat, J.M. Immunocytological studies of L-MAG expression regulation during myelination of embryonic brain cell cocultures. Dev. Neurosci., 2002, 24 (6), 495-503.
101. Schachner, M. Bartsch, U. Multiple functions of the myelinassociated glycoprotein MAG (siglec-4a) in formation and maintenance of myelin. Glia, 2000, 29 (2), 154-165.
102. Lee, J.; Gravel, M.; Zhang, R.; Thibault, P.; Braun, P.E. Process outgrowth in oligodendrocytes is mediated by CNP, a novel microtubule assembly myelin protein. J. Cell Biol., 2005, 170 (4), 661-673.
103. Johns, T.G.; Bernard, C.C. The structure and function of myelin oligodendrocyte glycoprotein. J. Neurochem., 1999, 72 (1), 1-9.
104. Campagnoni, A.T. Skoff, R.P. The pathobiology of myelin mutants reveal novel biological functions of the MBP and PLP genes. Brain Pathol., 2001, 11 (1), 74-91.
105. Stoffel, W.; Boison, D.; Bussow, H. Functional analysis in vivo of the double mutant mouse deficient in both proteolipid protein (PLP) and myelin basic protein (MBP) in the central nervous system. Cell Tissue Res., 1997, 289 (2), 195-206.
106. Dyer, C.A.; Phillbotte, T.; Wolf, M.K.; Billings-Gagliardi, S. Regulation of cytoskeleton by myelin components: studies on shiverer oligodendrocytes carrying an Mbp transgene. Dev. Neurosci., 1997, 19 (5), 395-409.
107. Jurevics, H.; Hostettler, J.; Sammond, D.W.; Nave, K.A.; Toews, A.D.; Morell, P. Normal metabolism but different physical properties of myelin from mice deficient in proteolipid protein. J. Neurosci. Res., 2003, 71 (6), 826-834.
108. Tanaka, H.; Ma, J.; Tanaka, K.F.; Takao, K.; Komada, M.; Tanda, K.; Suzuki, A.; Ishibashi, T.; Baba, H.; Isa, T.; Shigemoto, R.; Ono, K.; Miyakawa, T.; Ikenaka, K. Mice with Altered Myelin Proteolipid Protein Gene Expression Display Cognitive Deficits Accompanied by Abnormal Neuron-Glia Interactions and Decreased Conduction Velocities. J. Neurosci., 2009, 29 (26), 8363-8371.
109. Klugmann, M.; Schwab, M.H.; Puhlhofer, A.; Schneider, A.; Zimmermann, F.; Griffiths, I.R.; Nave, K.A. Assembly of CNS myelin in the absence of proteolipid protein. Neuron, 1997, 18 (1), 59-70.
110. Mobius, W.; Patzig, J.; Nave, K.A.; Werner, H.B. Phylogeny of proteolipid proteins: divergence, constraints, and the evolution of novel functions in myelination and neuroprotection. Neuron Glia Biol., 2008, 4 (2), 111-127.
111. Griffiths, I.; Klugmann, M.; Anderson, T.; Thomson, C.; Vouyiouklis, D.; Nave, K.A. Current concepts of PLP and its role in the nervous system. Microsc. Res. Tech., 1998, 41 (5), 344-358.
112. Uschkureit, T.; Sporkel, O.; Stracke, J.; Bussow, H.; Stoffel, W. Early Onset of Axonal Degeneration in Double (plp-/-mag-/-) and Hypomyelinosis in Triple (plp-/-mbp-/-mag-/-) Mutant Mice. J. Neurosci., 2000, 20 (14), 5225-5233.
113. Yin, X.; Peterson, J.; Gravel, M.; Braun, P.E.; Tra, B.D. CNP overexpression induces aberrant oligodendrocyte membranes and inhibits MBP accumulation and myelin compaction. J. Neurosci. Res., 1997, 50 (2), 238-247.
114. Hakak, Y.; Walker, J.R.; Li, C.; Wong, W.H.; Davis, K.L.; Buxbaum, J.D.; Haroutunian, V.; Fienberg, A.A. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc. Natl. Acad. Sci. USA, 2001, 98 (8), 4746-4751.
115. McCullumsmith, R.E.; Gupta, D.; Beneyto, M.; Kreger, E.; Haroutunian, V.; Davis, K.L.; Meador-Woodruff, J.H. Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia. Schizophr. Res., 2007, 90 (1-3), 15-27.
116. Li, C.; Tropak, M.B.; Gerlai, R.; Clapoff, S.; Abramow-Newerly, W.; Trapp, B.; Peterson, A.; Roder, J. Myelination in the absence of myelin-associated glycoprotein. Nature, 1994, 369 (6483), 747-750.
117. Quarles, R.H. A hypothesis about the relationship of myelinassociated glycoprotein's function in myelinated axons to its capacity to inhibit neurite outgrowth. Neurochem. Res., 2009, 34 (1), 79-86.
118. Filbin, M.T. Myelin-associated glycoprotein: a role in myelination and in the inhibition of axonal regeneration? Curr. Opin. Neurobiol., 1995, 5 (5), 588-595.
119. Karim, S.A.; Barrie, J.A.; McCulloch, M.C.; Montague, P.; Edgar, J.M.; Kirkham, D.; Anderson, T.J.; Nave, K.A.; Griffiths, I.R.; McLaughlin, M. PLP overexpression perturbs myelin protein composition and myelination in a mouse model of Pelizaeus-Merzbacher disease. Glia, 2007, 55 (4), 341-351.
120. Cohen, S.; Levi-Montalcini, R.; Hamburger, V. A Nerve Growth-Stimulating Factor Isolated from Sarcomas 37 and 180. Proc. Natl. Acad. Sci. USA, 1954, 40 (10), 1014-1018.
121. Levi-Montalcini, R.; Hamburger, V. Selective growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo. J. Exp. Zool., 1951, 116 (2), 321-361.
122. Aloe, L. Rita Levi-Montalcini and the discovery of NGF, the first nerve cell growth factor. Arch. Ital. Biol., 2011, 149 (2), 175-181.
123. Levi-Montalcini, R. The nerve growth factor 35 years later. Science, 1987, 237 (4819), 1154-1162.
124. Barde, Y.A.; Edgar, D.; Thoenen, H. Purification of a new neurotrophic factor from mammalian brain. EMBO J., 1982, 1 (5), 549-553.
125. Barde, Y.A.; Edgar, D.; Thoenen, H. New neurotrophic factors. Annu. Rev. Physiol., 1983, 45, 601-612.
126. Autio, H.; Matlik, K.; Rantamaki, T.; Lindemann, L.; Hoener, M.C.; Chao, M.; Arumae, U.; Castren, E. Acetylcholinesterase inhibitors rapidly activate Trk neurotrophin receptors in the mouse hippocampus. Neuropharmacology, 2011, 61 (8), 1291-1296.
127. Shu, Y.; Yang, Y.; Qiu, W.; Lu, Z.; Li, Y.; Bao, J.; Feng, M.; Hu, X. Neuroprotection by ulinastatin in experimental autoimmune encephalomyelitis. Neurochem. Res., 2011, 36 (11), 1969-1977.
128. Hasan, W.; Pedchenko, T.; Krizsan-Agbas, D.; Baum, L.; Smith, P.G. Sympathetic neurons synthesize and secrete pro-nerve growth factor protein. J. Neurobiol., 2003, 57 (1), 38-53.
129. Edwards, R.H.; Selby, M.J.; Garcia, P.D. Rutter, W.J. Processing of the native nerve growth factor precursor to form biologically active nerve growth factor. J. Biol. Chem., 1988, 263 (14), 6810-6815.
130. Fahnestock, M.; Yu, G.; Michalski, B.; Mathew, S.; Colquhoun, A.; Ross, G.M.; Coughlin, M.D. The nerve growth factor precursor proNGF exhibits neurotrophic activity but is less active than mature nerve growth factor. J. Neurochem., 2004, 89 (3), 581-592.
131. Clary, D.O.; Reichardt, L.F. An alternatively spliced form of the nerve growth factor receptor TrkA confers an enhanced response to neurotrophin 3. Proc. Natl. Acad. Sci. USA, 1994, 91 (23), 11133-11137.
132. Martin-Zanca, D.; Oskam, R.; Mitra, G.; Copeland, T.; Barbacid, M. Molecular and biochemical characterization of the human trk proto-oncogene. Mol. Cell Biol., 1989, 9 (1), 24-33.
133. Strohmaier, C.; Carter, B.D.; Urfer, R.; Barde, Y.A.; Dechant, G. A splice variant of the neurotrophin receptor trkB with increased specificity for brain-derived neurotrophic factor. EMBO J., 1996, 15 (13), 3332-3337.
134. Smith, C.A.; Farrah, T.; Goodwin, R.G. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell, 1994, 76 (6), 959-962.
135. Liepinsh, E.; Ilag, L.L.; Otting, G.; Ibanez, C.F. NMR structure of the death domain of the p75 neurotrophin receptor. EMBO J., 1997, 16 (16), 4999-5005.
136. Lee, R.; Kermani, P.; Teng, K.K.; Hempstead, B.L. Regulation of cell survival by secreted proneurotrophins. Science, 2001, 294 (5548), 1945-1948.
137. Nykjaer, A.; Lee, R.; Teng, K.K.; Jansen, P.; Madsen, P.; Nielsen, M.S.; Jacobsen, C.; Kliemannel, M.; Schwarz, E.; Willnow, T.E.; Hempstead, B.L.; Petersen, C.M. Sortilin is essential for proNGFinduced neuronal cell death. Nature, 2004, 427 (6977), 843-848.
138. Chen, Z.Y.; Ieraci, A.; Teng, H.; Dall, H.; Meng, C.X.; Herrera, D.G.; Nykjaer, A.; Hempstead, B.L.; Lee, F.S. Sortilin controls intracellular sorting of brain-derived neurotrophic factor to the regulated secretory pathway. J. Neurosci., 2005, 25 (26), 6156-6166.
139. Schecterson, L.C.; Bothwell, M. Neurotrophin receptors: Old friends with new partners. Dev. Neurobiol., 2010, 70 (5), 332-338.
140. Kuruvilla, R.; Zweifel, L.S.; Glebova, N.O.; Lonze, B.E.; Valdez, G.; Ye, H.; Ginty, D.D. A neurotrophin signaling cascade coordinates sympathetic neuron development through differential control of TrkA trafficking and retrograde signaling. Cell, 2004, 118 (2), 243-255.
141. Misko, T.P.; Radeke, M.J.; Shooter, E.M. Nerve growth factor in neuronal development and maintenance. J. Exp. Biol., 1987, 132, 177-190.
142. Hefti, F. Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. J. Neurosci., 1986, 6 (8), 2155-2162.
143. Williams, L.R.; Varon, S.; Peterson, G.M.; Wictorin, K.; Fischer, W.; Bjorklund, A.; Gage, F.H. Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection. Proc. Natl. Acad. Sci. USA, 1986, 83 (23), 9231-9235.
144. Aloe, L. Intraocular herpes simplex virus injection in neonatal rats induces sympathetic nerve cell destruction: effect of nerve growth factor. Int. J. Dev. Neurosci., 1987, 5 (4), 357-366.
145. Davies, S.W.; Beardsall, K. Nerve growth factor selectively prevents excitotoxin induced degeneration of striatal cholinergic neurones. Neurosci. Lett., 1992, 140 (2), 161-164.
146. Martinez-Serrano, A.; Bjorklund, A. Protection of the neostriatum against excitotoxic damage by neurotrophin-producing, genetically modified neural stem cells. J. Neurosci., 1996, 16 (15), 4604-4616.
147. Neumann, H.; Misgeld, T.; Matsumuro, K.; Wekerle, H. Neurotrophins inhibit major histocompatibility class II inducibility of microglia: involvement of the p75 neurotrophin receptor. Proc. Natl. Acad. Sci. USA, 1998, 95 (10), 5779-5784.
148. Villoslada, P.; Hauser, S.L.; Bartke, I.; Unger, J.; Heald, N.; Rosenberg, D.; Cheung, S.W.; Mobley, W.C.; Fisher, S.; Genain, C.P. Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system. J. Exp. Med., 2000, 191 (10), 1799-1806.
149. Abramchik, G.V.; Yermakova, S.S.; Kaliunov, V.N.; Tanina, R.M.; Tumilovich, M.K. The immunomodulatory effect of nerve growth factor. J. Neurosci. Res., 1988, 19 (3), 349-356.
150. Thorpe, L.W. Perez-Polo, J.R. The influence of nerve growth factor on the in vitro proliferative response of rat spleen lymphocytes. J. Neurosci. Res., 1987, 18 (1), 134-139.
151. Micera, A.; Properzi, F.; Triaca, V.; Aloe, L. Nerve growth factor antibody exacerbates neuropathological signs of experimental allergic encephalomyelitis in adult lewis rats. J. Neuroimmunol., 2000, 104 (2), 116-123.
152. Laudiero, L.B.; Aloe, L.; Levi-Montalcini, R.; Buttinelli, C.; Schilter, D.; Gillessen, S.; Otten, U. Multiple sclerosis patients express increased levels of beta-nerve growth factor in cerebrospinal fluid. Neurosci. Lett., 1992, 147 (1), 9-12.
153. Oudega, M.; Hagg, T. Nerve growth factor promotes regeneration of sensory axons into adult rat spinal cord. Exp. Neurol., 1996, 140 (2), 218-229.
154. Cohen, R.I.; Marmur, R.; Norton, W.T.; Mehler, M.F.; Kessler, J.A. Nerve Growth Factor and Neurotrophin-3 Differentially Regulate the Proliferation and Survival of Developing Rat Brain Oligodendrocytes. J. Neurosci., 1996, 16 (20), 6433-6442.
155. Althaus, H.H.; Kloppner, S.; Schmidt-Schultz, T.; Schwartz, P. Nerve growth factor induces proliferation and enhances fiber regeneration in oligodendrocytes isolated from adult pig brain. Neurosci. Lett., 1992, 135 (2), 219-223.
156. Frade, J.M.; Barde, Y.A. Microglia-derived nerve growth factor causes cell death in the developing retina. Neuron, 1998, 20 (1), 35-41.
157. Santambrogio, L.; Benedetti, M.; Chao, M.V.; Muzaffar, R.; Kulig, K.; Gabellini, N.; Hochwald, G. Nerve growth factor production by lymphocytes. J. Immunol., 1994, 153 (10), 4488-4495.
158. Ehrhard, P.B.; Erb, P.; Graumann, U.; Otten, U. Expression of nerve growth factor and nerve growth factor receptor tyrosine kinase Trk in activated CD4-positive T-cell clones. Proc. Natl. Acad. Sci. USA, 1993, 90 (23), 10984-10988.
159. Brodie, C.E.; Gelfand, W. Functional nerve growth factor receptors on human B lymphocytes. Interaction with IL-2. J. Immunol., 1992, 148 (11), 3492-3497.
160. Leon, A.; Buriani, A.; Dal Toso, R.; Fabris, M.; Romanello, S.; Aloe, L.; Levi-Montalcini, R. Mast cells synthesize, store, and release nerve growth factor. Proc. Natl. Acad. Sci. USA, 1994, 91 (9), 3739-3743.
161. Micera, A.; De Simone, R.; Aloe, L. Elevated levels of nerve growth factor in the thalamus and spinal cord of rats affected by experimental allergic encephalomyelitis. Arch. Ital. Biol., 1995, 133 (2), 131-142.
162. Gallo, A.; Rovaris, M.; Riva, R.; Ghezzi, A.; Benedetti, B.; Martinelli, V.; Falini, A.; Comi, G.; Filippi, M. Diffusion-tensor magnetic resonance imaging detects normal-appearing white matter damage unrelated to short-term disease activity in patients at the earliest clinical stage of multiple sclerosis. Arch. Neurol., 2005, 62 (5), 803-808.
163. Trapp, B.D.; Peterson, J.; Ransohoff, R.M.; Rudick, R.; Mork, S.; Bo, L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med., 1998, 338 (5), 278-285.
164. Kuhlmann, T.; Lingfeld, G.; Bitsch, A.; Schuchardt, J.; Bruck, W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain, 2002, 125 (Pt 10), 2202-2212.
165. Dutta, R.; McDonough, J.; Yin, X.; Peterson, J.; Chang, A.; Torres, T.; Gudz, T.; Macklin, W.B.; Lewis, D.A.; Fox, R.J.; Rudick, R.; Mirnics, K.; Tra, B.D. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann. Neurol., 2006, 59 (3), 478-489.
166. Bjartmar, C.; Kidd, G.; Mork, S.; Rudick, R.; Tra, B.D. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann. Neurol., 2000, 48 (6), 893-901.
167. Lovas, G.; Szilagyi, N.; Majtenyi, K.; Palkovits, M.; Komoly, S. Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain. 2000, 123 (Pt 2), 308-317.
168. Kornek, B.; Storch, M.K.; Weissert, R.; Wallstroem, E.; Stefferl, A.; Olsson, T.; Linington, C.; Schmidbauer, M.; Lassmann, H. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am. J. Pathol., 2000, 157 (1), 267-276.
169. Trapp, B.D. Nave, K.A. Multiple sclerosis: an immune or neurodegenerative disorder? Annu. Rev. Neurosci., 2008, 31, 247-269.
170. Dutta, R.B.; Tra, D. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology, 2007, 68 (22 Suppl 3), S22-S31.
171. Bjartmar, C.; Wujek, J.R.; Tra, B.D. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J. Neurol. Sci., 2003, 206 (2), 165-171.
172. Bruck, W.; Stadelmann, C. Inflammation and degeneration in multiple sclerosis. Neurol. Sci., 2003, 24 (Suppl 5), S265-S267.
173. Fine, E.G.; Decosterd, I.; Papaloizos, M.; Zurn, A.D.; Aebischer, P. GDNF and NGF released by synthetic guidance channels support sciatic nerve regeneration across a long gap. Eur. J. Neurosci., 2002, 15 (4), 589-601.
174. Madduri, S.; Papaloizos, M.; Gander, B. Synergistic effect of GDNF and NGF on axonal branching and elongation in vitro. Neurosci. Res., 2009, 65 (1), 88-97.
175. Sanchez, I.; Hassinger, L.; Paskevich, P.A.; Shine, H.D.; Nixon, R.A. Oligodendroglia regulate the regional expansion of axon caliber and local accumulation of neurofilaments during development independently of myelin formation. J. Neurosci., 1996, 16 (16), 5095-5105.
176. Kaplan, M.R.; Meyer-Franke, A.; Lambert, S.; Bennett, V.; Duncan, I.D.; Levinson, S.R.; Barres, B.A. Induction of sodium channel clustering by oligodendrocytes. Nature, 1997, 386 (6626), 724-728.
177. Griffiths, I.; Klugmann, M.; Anderson, T.; Yool, D.; Thomson, C.; Schwab, M.H.; Schneider, A.; Zimmermann, F.; McCulloch, M.; Nadon, N.; Nave, K.A. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science, 1998, 280 (5369), 1610-1613.
178. Chan, J.R.; Watkins, T.A.; Cosgaya, J.M.; Zhang, C.; Chen, L.; Reichardt, L.F.; Shooter, E.M.; Barres, B.A. NGF Controls Axonal Receptivity to Myelination by Schwann Cells or Oligodendrocytes. Neuron, 2004, 43 (2), 183-191.
179. Akassoglou, K.; Bauer, J.; Kassiotis, G.; Pasparakis, M.; Lassmann, H.; Kollias, G.; Probert, L. Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: models for multiple sclerosis with primary oligodendrogliopathy. Am. J. Pathol., 1998, 153 (3), 801-813.
180. Furukawa, S.; Furukawa, Y.; Satoyoshi, E.; Hayashi, K. Synthesis and secretion of nerve growth factor by mouse astroglial cells in culture. Biochem. Biophys. Res. Commun., 1986, 136 (1), 57-63.
181. Yamakuni, T.; Ozawa, F.; Hishinuma, F.; Kuwano, R.; Takahashi, Y.; Amano, T. Expression of beta-nerve growth factor mRNA in rat glioma cells and astrocytes from rat brain. FEBS Lett., 1987, 223 (1), 117-121.
182. Vemuri, G.S.; McMorris, F.A. Oligodendrocytes and their precursors require phosphatidylinositol 3-kinase signaling for survival. Development, 1996, 122 (8), 2529-2537.
183. Bentley, C.A.; Lee, K.F. p75 is important for axon growth and schwann cell migration during development. J. Neurosci., 2000, 20 (20), 7706-7715.
184. Anton, E.S.; Weskamp, G.; Reichardt, L.F.; Matthew, W.D. Nerve growth factor and its low-affinity receptor promote Schwann cell migration. Proc. Natl. Acad. Sci. USA, 1994, 91 (7), 2795-2799.
185. Chang, A.; Nishiyama, A.; Peterson, J.; Prineas, J.; Tra, B.D. NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. J. Neurosci., 2000, 20 (17), 6404-6412.
186. Oderfeld-Nowak, B.; Zaremba, M.; Kwiatkowska-Patzer, B.; Lipkowski, A.W.; Kurkowska-Jastrzebska, I.; Triaca, V.; Aloe, L. NG2 positive cells of rat spinal cord activated during experimental autoimmune encephalomyelitis are spatially associated with radially oriented astroglia and express p75 receptor: a role for nerve growth factor in oligodendrocyte progenitor migration? Arch. Ital. Biol., 2009, 147 (4), 105-115.
187. Carroll, W.M.; Jennings, A.R. Early recruitment of oligodendrocyte precursors in CNS demyelination. Brain, 1994, 117 (Pt 3), 563-578.
188. Wolswijk, G. Oligodendrocyte survival, loss and birth in lesions of chronic-stage multiple sclerosis. Brain, 2000, 123 (Pt 1), 105-115.
189. Prineas, J.W.; Barnard, R.O.; Kwon, E.E.; Sharer, L.R.; Cho, E.S. Multiple sclerosis: remyelination of nascent lesions. Ann. Neurol., 1993, 33 (2), 137-151.
190. Kohama, I.; Lankford, K.L.; Preiningerova, J.; White, F.A.; Vollmer, T.L.; Kocsis, J.D. Transplantation of cryopreserved adult human Schwann cells enhances axonal conduction in demyelinated spinal cord. J. Neurosci., 2001, 21 (3), 944-950.
191. Marty, S.; Dusart, I.; Peschanski, M. Glial changes following an excitotoxic lesion in the CNS--I. Microglia/macrophages. Neuroscience, 1991, 45 (3), 529-539.
192. Stichel, C.C.; Muller, H.W. Extensive and long-lasting changes of glial cells following transection of the postcommissural fornix in the adult rat. Glia, 1994, 10 (2), 89-100.
193. Itoyama, Y.; Webster, H.D.; Richardson, E.P., Jr.; Tra, B.D. Schwann cell remyelination of demyelinated axons in spinal cord multiple sclerosis lesions. Ann. Neurol., 1983, 14 (3), 339-346.
194. Dusart, I.; Isacson, O.; Nothias, F.; Gumpel, M.; Peschanski, M. Presence of Schwann cells in neurodegenerative lesions of the central nervous system. Neurosci. Lett., 1989, 105 (3), 246-250.
195. Beattie, M.S.; Bresnahan, J.C.; Komon, J.; Tovar, C.A.; Van Meter, M.; Anderson, D.K.; Faden, A.I.; Hsu, C.Y.; Noble, L.J.; Salzman, S.; Young, W. Endogenous repair after spinal cord contusion injuries in the rat. Exp. Neurol., 1997, 148 (2), 453-463.
196. Raine, C.S.; Traugott, U.; Stone, S.H. Glial bridges and Schwann cell migration during chronic demyelination in the C.N.S. J. Neurocytol., 1978, 7 (5), 541-553.
197. Maniwa, S.; Iwata, A.; Hirata, H.; Ochi, M. Effects of neurotrophic factors on chemokinesis of Schwann cells in culture. Scand. J. Plast. Reconstr. Surg. Hand. Surg., 2003, 37 (1), 14-17.
198. Cornejo, M.; Nambi, D.; Walheim, C.; Somerville, M.; Walker, J.; Kim, L.; Ollison, L.; Diamante, G.; Vyawahare, S.; de Bellard, M.E. Effect of NRG1, GDNF, EGF and NGF in the migration of a Schwann cell precursor line. Neurochem. Res., 2010, 35 (10), 1643-1651.
199. McTigue, D.M.; Horner, P.J.; Stokes, B.T.; Gage, F.H. Neurotrophin-3 and brain-derived neurotrophic factor induce oligodendrocyte proliferation and myelination of regenerating axons in the contused adult rat spinal cord. J. Neurosci., 1998, 18 (14), 5354-5365.
200. De Santi, L.; Annunziata, P.; Sessa, E.; Bramanti, P. Brain-derived neurotrophic factor and TrkB receptor in experimental autoimmune encephalomyelitis and multiple sclerosis. J. Neurol. Sci., 2009, 287 (1-2), 17-26.
201. Du, Y.; Fischer, T.Z.; Clinton-Luke, P.; Lercher, L.D.; Dreyfus, C.F. Distinct effects of p75 in mediating actions of neurotrophins on basal forebrain oligodendrocytes. Mol. Cell Neurosci., 2006, 31 (2), 366-375.
202. Djalali, S.; Holtje, M.; Grosse, G.; Rothe, T.; Stroh, T.; Grosse, J.; Deng, D.R.; Hellweg, R.; Grantyn, R.; Hortnagl, H.; Ahnert-Hilger, G. Effects of brain-derived neurotrophic factor (BDNF) on glial cells and serotonergic neurones during development. J. Neurochem., 2005, 92 (3), 616-627.
203. Cellerino, A.; Carroll, P.; Thoenen, H.; Barde, Y.A. Reduced size of retinal ganglion cell axons and hypomyelination in mice lacking brain-derived neurotrophic factor. Mol. Cell Neurosci., 1997, 9 (5-6), 397-408.
204. Du, Y.; Fischer, T.Z.; Lee, L.N.; Lercher, L.D.; Dreyfus, C.F. Regionally specific effects of BDNF on oligodendrocytes. Dev. Neurosci., 2003, 25 (2-4), 116-126.
205. Makar, T.K.; Bever, C.T.; Singh, I.S.; Royal, W.; Sahu, S.N.; Sura, T.P.; Sultana, S.; Sura, K.T.; Patel, N.; Dhib-Jalbut, S.; Trisler, D. Brain-derived neurotrophic factor gene delivery in an animal model of multiple sclerosis using bone marrow stem cells as a vehicle. J. Neuroimmunol., 2009, 210 (1-2), 40-51.
206. Lee, D.H.; Geyer, E.; Flach, A.C.; Jung, K.; Gold, R.; Flugel, A.; Linker, R.A.; Luhder, F. Central nervous system rather than immune cell-derived BDNF mediates axonal protective effects early in autoimmune demyelination. Acta Neuropathol., 2012, 123 (2), 247-258.
207. Micera, A.; Vigneti, E.; Aloe, L. Changes of NGF presence in nonneuronal cells in response to experimental allergic encephalomyelitis in Lewis rats. Exp. Neurol., 1998, 154 (1), 41-46.
208. Koltzenburg, M.; Bennett, D.L.; Shelton, D.L.; McMahon, S.B. Neutralization of endogenous NGF prevents the sensitization of nociceptors supplying inflamed skin. Eur. J. Neurosci., 1999, 11 (5), 1698-1704.
209. Cho, H.J.; Kim, S.Y.; Park, M.J.; Kim, D.S.; Kim, J.K.; Chu, M.Y. Expression of mRNA for brain-derived neurotrophic factor in the dorsal root ganglion following peripheral inflammation. Brain Res., 1997, 749 (2), 358-362.
210. Hofman, F.M.; Hinton, D.R.; Johnson, K.; Merrill, J.E. Tumor necrosis factor identified in multiple sclerosis brain. J. Exp. Med., 1989, 170 (2), 607-612.
211. Drulovic, J.; Mostarica-Stojkovic, M.; Levic, Z.; Stojsavljevic, N.; Pravica, V.; Mesaros, S. Interleukin-12 and tumor necrosis factoralpha levels in cerebrospinal fluid of multiple sclerosis patients. J. Neurol. Sci., 1997, 147 (2), 145-150.
212. Zhu, W.; Frost, E.E.; Begum, F.; Vora, P.; Au, K.; Gong, Y.; Macneil, B.; Pillai, P.; Namaka, M. The role of dorsal root ganglia activation and brain-derived neurotrophic factor in multiple sclerosis. J. Cell Mol. Med., 2012, 16 (8), 1856-1865.
213. Arnett, H.A.; Mason, J.; Marino, M.; Suzuki, K.; Matsushima, G.K.; Ting, J.P. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat. Neurosci., 2001, 4 (11), 1116-1122.
214. Namaka, M.; Kapoor, S.; Simms, L.; Leong, C.; Grossberndt, A.; Prout, M.; Frost, E.; Esfahani, F.; Gomori, A.; Mulvey, M.R. Molecular Mimicry and Multiple Sclerosis. Neural Regen. Res., 2011, 6 (17), 1322-1333.
215. Loma, I.; Heyman, R. Multiple sclerosis: pathogenesis and treatment. Curr. Neuropharmacol., 9 (3), 409-416.
216. Zhang, J.; Hutton, G.; Zang, Y. A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis. Clin. Ther., 2002, 24 (12), 1998-2021.
217. Boutros, T.; Croze, E.; Yong, V.W. Interferon-beta is a potent promoter of nerve growth factor production by astrocytes. J. Neurochem., 1997, 69 (3), 939-946.
218. Biernacki, K.; Antel, J.P.; Blain, M.; Narayanan, S.; Arnold, D.L.; Prat, A. Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis. Arch. Neurol., 2005, 62 (4), 563-568.
219. Azoulay, D.; Vachapova, V.; Shihman, B.; Miler, A.; Karni, A. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J. Neuroimmunol., 2005, 167 (1-2), 215-218.
220. Vollmer, T.; Stewart, T.; Baxter, N. Mitoxantrone and cytotoxic drugs' mechanisms of action. Neurology, 2010, 74 (Suppl 1), S41-S46.
221. Namaka, M.P.; Turcotte, D.A.; Klowak, M.; Leong, C.M.; Grossberndt, A.; Le Dorze, J.-A.; Prout, M.E.; Andresen, S.; Melanson, M.J.; Frost, E.E.; Doupe, M. Early Mitoxantrone-Induced Cardiotoxicity Detected in Secondary Progressive Multiple Sclerosis. J. Popul. Therap. Clin. Pharmacol., 2011, 3, 449-458.
222. Brown, B.A. Natalizumab in the treatment of multiple sclerosis. Ther. Clin. Risk Manag., 2009, 5 (3), 585-594.
223. Cohen, J.A.; Chun, J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann. Neurol., 2011, 69 (5), 759-777.
224. Althaus, H.H. Remyelination in multiple sclerosis: a new role for neurotrophins? Prog. Brain Res., 2004, 146, 415-432.
225. Flugel, A.; Matsumuro, K.; Neumann, H.; Klinkert, W.E.; Birnbacher, R.; Lassmann, H.; Otten, U.; Wekerle, H. Antiinflammatory activity of nerve growth factor in experimental autoimmune encephalomyelitis: inhibition of monocyte transendothelial migration. Eur. J. Immunol., 2001, 31 (1), 11-22.
226. Kramer, R.; Zhang, Y.; Gehrmann, J.; Gold, R.; Thoenen, H.; Wekerle, H. Gene transfer through the blood-nerve barrier: NGFengineered neuritogenic T lymphocytes attenuate experimental autoimmune neuritis. Nat. Med., 1995, 1 (11), 1162-1166.
227. Tafreshi, P.A. Nerve growth factor prevents demyelination, cell death and progression of the disease in experimental allergic encephalomyelitis. Iran J. Allergy Asthma Immunol., 2006, 5 (4), 177-181.
228. Triaca, V.; Tirassa, P.; Aloe, L. Presence of nerve growth factor and TrkA expression in the SVZ of EAE rats: evidence for a possible functional significance. Exp. Neurol., 2005, 191 (1), 53-64.
229. Kalinowska-Lyszczarz, A.; Pawlak, M.A.; Michalak, S.; Losy, J. Cognitive deficit is related to immune-cell beta-NGF in multiple sclerosis patients. J. Neurol. Sci., 2012, 321 (1-2), 43-48.
230. Urshansky, N.; Mausner-Fainberg, K.; Auriel, E.; Regev, K.; Farhum, F.; Karni, A. Dysregulated neurotrophin mRNA production by immune cells of patients with relapsing remitting multiple sclerosis. J. Neurol. Sci., 2010, 295 (1-2), 31-37.
231. Thorne, R.G.; Frey, W.H., 2nd. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin. Pharmacokinet., 2001, 40 (12), 907-946.
232. Poduslo, J.F.; Curran, G.L. Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Brain Res. Mol. Brain Res., 1996, 36 (2), 280-286.
233. Olson, L.; Nordberg, A.; von Holst, H.; Backman, L.; Ebendal, T.; Alafuzoff, I.; Amberla, K.; Hartvig, P.; Herlitz, A.; Lilja, A. Nerve growth factor affects 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report). J. Neural Transm. Park. Dis. Dement. Sect., 1992, 4 (1), 79-95.
234. Jonhagen, E.M.; Nordberg, A.; Amberla, K.; Backman, L.; Ebendal, T.; Meyerson, B.; Seiger, L.O.; Shigeta, M.; Theodorsson, E.; Viitanen, M.; Winblad, B.; Wahlund, L.O. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord., 1998, 9 (5), 246-257.
235. Chen, K.S.; Gage, F.H. Somatic gene transfer of NGF to the aged brain: behavioral and morphological amelioration. J. Neurosci., 1995, 15 (4), 2819-2825.
236. Tuszynski, M.H.; Gage, F.H. Somatic gene therapy for nervous system disease. Ciba Found. Symp., 1996, 196, 85-94.
237. Tuszynski, M.H.; Blesch, A. Nerve growth factor: from animal models of cholinergic neuronal degeneration to gene therapy in Alzheimer's disease. Prog. Brain Res., 2004, 146, 441-449.
238. Tuszynski, M.H.; Thal, L.; Pay, M.; Salmon, D.P.; Sang, H.U.; Bakay, R.; Patel, P.; Blesch, A.; Vahlsing, H.L.; Ho, G.; Tong, G.; Potkin, S.G.; Fallon, J.; Hansen, L.; Mufson, E.J.; Kordower, J.H.; Gall, C.; Conner, J. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med., 2005, 11 (5), 551-555.
239. Mandel, R.J. CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease. Curr. Opin. Mol. Ther., 12 (2), 240-247.
240. Bishop, K.M.; Hofer, E.K.; Mehta, A.; Ramirez, A.; Sun, L.; Tuszynski, M.; Bartus, R.T. Therapeutic potential of CERE-110 (AAV2-NGF): targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons. Exp. Neurol., 2008, 211 (2), 574-584.
241. Lindvall, O.L.; Wahlberg, U. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease? Exp. Neurol., 2008, 209 (1), 82-88.
242. Eriksdotter-Jonhagen, M.; Linderoth, B.; Lind, G.; Aladellie, L.; Almkvist, O.; Andreasen, N.; Blennow, K.; Bogdanovic, N.; Jelic, V.; Kadir, A.; Nordberg, A.; Sundstrom, E.; Wahlund, L.O.; Wall, A.; Wiberg, M.; Winblad, B.; Seiger, A.; Almqvist, P.; Wahlberg, L. Encapsulated cell biodelivery of nerve growth factor to the Basal forebrain in patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord., 33 (1), 18-28.
243. Wahlberg, L.U.; Lind, G.; Almqvist, P.M.; Kusk, P.; Tornoe, J.; Juliusson, B.; Soderman, M.; Sellden, E.; Seiger, A.; Eriksdotter-Jonhagen, M.; Linderoth, B. Targeted delivery of nerve growth factor via encapsulated cell biodelivery in Alzheimer disease: a technology platform for restorative neurosurgery. J. Neurosurg., 117 (2), 340-347.
244. Saragovi, H.U.; Gehring, K. Development of pharmacological agents for targeting neurotrophins and their receptors. Trends Pharmacol. Sci., 2000, 21 (3), 93-98.
245. Colangelo, A.M.; Bianco, M.R.; Vitagliano, L.; Cavaliere, C.; Cirillo, G.; De Gioia, L.; Diana, D.; Colombo, D.; Redaelli, C.; Zaccaro, L.; Morelli, G.; Papa, M.; Sarmientos, P.; Alberghina, L.; Martegani, E. A new nerve growth factor-mimetic peptide active on neuropathic pain in rats. J. Neurosci., 2008, 28 (11), 2698-2709.
246. Covaceuszach, S.; Capsoni, S.; Ugolini, G.; Spirito, F.; Vignone, D.; Cattaneo, A. Development of a non invasive NGF-based therapy for Alzheimer's disease. Curr. Alzheimer Res., 2009, 6 (2), 158-170.
247. Chen, W.G.; Chang, Q.; Lin, Y.; Meissner, A.; West, A.E.; Griffith, E.C.; Jaenisch, R.; Greenberg, M.E. Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science, 2003, 302 (5646), 885-889.
248. Chang, Q.; Khare, G.; Dani, V.; Nelson, S.; Jaenisch, R. The disease progression of mecp2 mutant mice is affected by the level of BDNF expression. Neuron, 2006, 49 (3), 341-348.
249. Althaus, H.H.; Kloppner, S.; Klopfleisch, S.; Schmitz, M. Oligodendroglial cells and neurotrophins: a polyphonic cantata in major and minor. J. Mol. Neurosci., 2008, 35 (1), 65-79.
250. Albrecht, D.; Garcia, L.; Cartier, L.; Kettlun, A.M.; Vergara, C.; Collados, L.; Valenzuela, M.A. Trophic factors in cerebrospinal fluid and spinal cord of patients with tropical spastic paraparesis, HIV, and Creutzfeldt-Jakob disease. AIDS Res. Hum. Retroviruses, 2006, 22 (3), 248-254.